MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-03-2025
IDEXX Laboratories Operating Income 2011-2025 | IDXX
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income IDEXX Laboratories
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.13 B | 1.1 B | 899 M | 932 M | 695 M | 553 M | 491 M | 413 M | 350 M | 300 M | 260 M | 267 M | 263 M | 236 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.13 B | 236 M | 563 M |
Quarterly Operating Income IDEXX Laboratories
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 355 M | 373 M | 317 M | - | 304 M | 264 M | 299 M | - | 275 M | 296 M | 280 M | - | 245 M | 179 M | 248 M | - | 226 M | 259 M | 248 M | - | 172 M | 193 M | 144 M | 116 M | 140 M | 164 M | 133 M | 115 M | 117 M | 146 M | 113 M | 97.8 M | 100 M | 123 M | 92.2 M | 83.8 M | 88.5 M | 104 M | 73.8 M | 66.9 M | 71.9 M | 88.3 M | 72.8 M | 34.8 M | 72.2 M | 83.2 M | 70 M | 61.3 M | 65.5 M | 78.8 M | 61.2 M | 63.4 M | 62.9 M | 75.8 M | 60.4 M | 55.3 M | 56.1 M | 71.3 M | 53.5 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 373 M | 34.8 M | 145 M |
Operating Income of other stocks in the Diagnostics research industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Akumin
AKU
|
-28.1 M | - | -17.87 % | $ 25.9 M |  Canada |
|
Centogene N.V.
CNTG
|
-46 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Chembio Diagnostics
CEMI
|
-23.6 M | - | 0.22 % | $ 16.8 M |  USA |
 |
Brainsway Ltd.
BWAY
|
-5 M | $ 19.29 | -1.73 % | $ 99.4 M |  Israel |
 |
Castle Biosciences
CSTL
|
8.67 M | $ 40.09 | -0.27 % | $ 1.11 B | USA |
 |
Burning Rock Biotech Limited
BNR
|
-797 M | $ 21.26 | -2.34 % | $ 229 M |  China |
 |
Accelerate Diagnostics
AXDX
|
-14 M | - | -61.36 % | $ 2.46 M | USA |
 |
Biocept
BIOC
|
-32 M | - | -13.05 % | $ 7.29 M | USA |
 |
Danaher Corporation
DHR
|
4.86 B | $ 231.47 | 0.28 % | $ 169 B | USA |
 |
DarioHealth Corp.
DRIO
|
-56.2 M | $ 10.04 | -0.99 % | $ 285 M | Israel |
 |
DexCom
DXCM
|
598 M | $ 67.42 | 0.84 % | $ 26 B | USA |
 |
Enzo Biochem
ENZ
|
-12.4 M | - | -8.98 % | $ 14.8 K | USA |
 |
BioNano Genomics
BNGO
|
-104 M | $ 1.52 | -0.65 % | $ 1.93 M | USA |
 |
Exact Sciences Corporation
EXAS
|
-876 M | $ 101.54 | -0.05 % | $ 18.8 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-20.8 M | - | -20.0 % | $ 1.06 M | USA |
 |
Fulgent Genetics
FLGT
|
-73.9 M | $ 27.01 | -0.55 % | $ 817 M | USA |
 |
Global Cord Blood Corporation
CO
|
609 M | - | - | $ 399 M | China |
 |
Genetron Holdings Limited
GTH
|
-518 M | - | 0.12 % | $ 80.1 M | China |
 |
DermTech
DMTK
|
-104 M | - | -11.32 % | $ 2.94 M | USA |
 |
CareDx, Inc
CDNA
|
-203 M | $ 19.73 | -1.45 % | $ 1.06 B | USA |
 |
Celcuity
CELC
|
-113 M | $ 102.61 | 0.25 % | $ 4.05 B | USA |
 |
Anixa Biosciences
ANIX
|
-13.8 M | $ 3.42 | 3.64 % | $ 109 K | USA |
 |
Co-Diagnostics
CODX
|
-42.7 M | $ 0.24 | -1.79 % | $ 7.04 M | USA |
 |
IQVIA Holdings
IQV
|
2.2 B | $ 226.02 | 0.39 % | $ 41 B | USA |
 |
Motus GI Holdings
MOTS
|
-11.9 M | - | -34.28 % | $ 263 K | Israel |
 |
Guardant Health
GH
|
-444 M | $ 102.38 | -0.12 % | $ 12.6 B | USA |
 |
NeoGenomics
NEO
|
-92.1 M | $ 12.3 | -0.97 % | $ 1.56 B | USA |
 |
Neogen Corporation
NEOG
|
-1.06 B | $ 7.14 | -0.14 % | $ 1.55 B | USA |
 |
Aspira Women's Health
AWH
|
-32.8 M | - | -6.19 % | $ 10.5 M | USA |
 |
National Research Corporation
NRC
|
40 M | $ 18.81 | -1.05 % | $ 462 M | USA |
 |
Heska Corporation
HSKA
|
-20.3 M | - | - | $ 1.31 B | USA |
 |
Organovo Holdings
ONVO
|
-12.6 M | - | -2.3 % | $ 19.4 M | USA |
 |
OpGen
OPGN
|
325 K | - | -16.95 % | $ 1.54 M | USA |
 |
OPKO Health
OPK
|
-152 M | $ 1.3 | -0.76 % | $ 902 M | USA |
 |
Illumina
ILMN
|
-833 M | $ 135.32 | -0.64 % | $ 21.5 B | USA |
 |
Charles River Laboratories International
CRL
|
227 M | $ 203.16 | 0.14 % | $ 10.4 B | USA |
 |
ENDRA Life Sciences
NDRA
|
-10.8 M | $ 5.1 | - | $ 2.74 M | USA |
 |
Pacific Biosciences of California
PACB
|
-334 M | $ 1.88 | 3.3 % | $ 477 M | USA |
 |
PerkinElmer
PKI
|
347 M | - | -0.91 % | $ 14.7 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
1.35 B | $ 175.92 | 0.48 % | $ 19.5 B | USA |
|
Biodesix
BDSX
|
-34.5 M | $ 6.82 | 1.04 % | $ 884 M | USA |
 |
Myriad Genetics
MYGN
|
-124 M | $ 6.55 | -0.15 % | $ 593 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
1.09 B | $ 254.46 | 0.52 % | $ 21.3 B | USA |
 |
ICON Public Limited Company
ICLR
|
1.1 B | $ 183.68 | 0.33 % | $ 15.2 B |  Irlanda |